Why Novavax (NVAX) Stock Rose 4.21% in 10 Minutes After Q3 Earnings on Nov 5, 2026
EPS of -$0.19 came in above the -$0.35 estimate; revenue of $68.3 million came in above the $50.43 million estimate.
- NVAX rose 4.21% in the 10 minutes after the 08:00:00 ET headline, from $10.70 to $11.15.
- The 4.21% gain was larger than any reaction MoveSurge measured after Novavax headlines between Aug 7, 2026 and Nov 4, 2026; the largest of those was -1.61% in 10 minutes, on Oct 29, 2026.
- 42,146 shares changed hands in those 10 minutes, 38.6 times the stock's normal volume for that stretch of the session.
08:00:00 ET
Reaction by asset (real prices)
| Asset | 2m before | At release | +1m | +10m | +1m % | +10m % |
|---|---|---|---|---|---|---|
| NVAX Volume 38.6× normal in 15 min |
10.70 | 10.70 | 11.16 | 11.15 | +4.30% | +4.21% |
Novavax (NVAX) shares rose 4.21% in the 10 minutes after its Q3 results reached the MoveSurge news feed at 08:00:00 ET on Thursday, November 5, 2026. EPS of -$0.19 came in above the -$0.35 estimate; revenue of $68.3 million came in above the $50.43 million estimate.
NVAX in the first 10 minutes
The line that crossed at 08:00:00 ET: “NVAX Q3: EPS -0.19 vs -0.35 est”
From a reference price of $10.70 just before the headline, the stock was up 4.30% after one minute and up 4.21%, at $11.15, after 10 minutes. The first-minute move held. 42,146 shares changed hands in those 10 minutes, 38.6 times the stock's normal volume for that stretch of the session. The headline crossed in pre-market trading, 1 hour 30 minutes before the 9:30 ET open.
Novavax Q3 results against estimates
| Measure | Reported | Estimate | Result |
|---|---|---|---|
| EPS | -$0.19 | -$0.35 | Beat |
| Revenue | $68.3 million | $50.43 million | Beat |
Novavax FY26 guidance
| Measure | New range | Prior range | Estimate | Change |
|---|---|---|---|---|
| Revenue | $385 million to $415 million | $235 million to $275 million | $380.29 million | Raised |
How NVAX traded after earlier earnings releases
| Report | EPS vs estimate | Revenue vs estimate | First move |
|---|---|---|---|
| Aug 6, 2026 | -$0.32 vs -$0.37 | $56.7 million vs $52.51 million | not measured |
Other NVAX headlines on November 5, 2026
- 08:57 ET: “Novavax executive says company is exploring a reduction of more than 50% in its operating footprint by consolidating buildings and laboratories” (+0.29% in 10 minutes)
Earlier NVAX headlines and the measured reaction
The 4.21% gain was larger than any reaction MoveSurge measured after Novavax headlines between Aug 7, 2026 and Nov 4, 2026; the largest of those was -1.61% in 10 minutes, on Oct 29, 2026.
- Oct 29, 2026, 09:38 ET: “Novavax could receive a $225 million milestone payment when its combination vaccine launches in the U.S.” (-1.61% in 10 minutes)
Novavax at a glance
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Market value | $1.76 billion (as of Nov 5, 2026) |
Prices are closes of 1-minute bars. Each move on this page is measured from the last completed bar before its headline.
How did Novavax stock react to its Q3 earnings on November 5, 2026?
The stock rose 4.21% in the 10 minutes after its Q3 results crossed at 08:00:00 ET. EPS of -$0.19 came in above the -$0.35 estimate; revenue of $68.3 million came in above the $50.43 million estimate.
How far did NVAX move after the headline?
From $10.70 just before the headline to $11.15 10 minutes later, a +4.21% move.
What did Novavax guide for revenue?
Revenue guidance of $385 million to $415 million, replacing $235 million to $275 million; the estimate was $380.29 million (raised).
Sources
-
NVAX headline and measured reaction, Nov 5, 2026
— MoveSurge
The headline as it crossed, its timestamp, and the measured price reaction reported on this page.
Never miss the next market-moving story
Follow the core market-moving feed across equities, macro, currencies and commodities. Your subscription includes price moves after the news, search, watchlists, alerts and research tools.
Go live — 7 days for $29 Watch live headlines -- free